Bed Bath & Beyond posts disappointing results after low inventory hurt business in the holiday quarter

Bed Bath & Beyond posts disappointing results after low inventory hurt business in the holiday quarter


Bed Bath and Beyond on Wednesday reported a surprising holiday-quarter loss, as the company ran low on inventory and struggled to move merchandise out of congested ports and onto shelves.

Shares fell more than 10% in premarket trading, as investors weighed the news.

CEO Mark Tritton said out-of-stock merchandise caused the company to miss out on about $175 million in fiscal fourth-quarter sales. That’s higher than the prior quarter, when supply chain bottlenecks cost the company about $100 million.

Tritton said in a CNBC interview that the home goods retailer is disappointed by its results. He said “major headwinds in the macro environment” have slowed the company’s turnaround efforts. For instance, he said, moving goods costs more, and some best-selling items from national brands are in short supply due to missing components like microchips that go into vacuums. Plus, he said, the majority of its seasonal merchandise got stuck at ports and arrived late.

He said some of those challenges have carried into the current quarter.

Still, Tritton said, Bed Bath is making progress with its transformation. He said it is investing in technology, welcoming back customers with postcards and targeted emails and expanding its more profitable private label business.

Bed Bath has been on a bumpy ride, as Target veteran Tritton has sought to refresh the retailer’s brand with the launch of private label products, store remodels and closures of underperforming locations. Its stock has been drawn into meme-stock rallies along with AMC Entertainment and GameStop. It has also been under pressure from investors — including activist Ryan Cohen, chairman of GameStop and founder of Chewy.

The retailer recently struck a deal with Cohen’s firm, RC Ventures, by agreeing to add new board members and explore whether it should spin off or sell its BuyBuy Baby business, which has been one of its bright spots.

Bed Bath on Wednesday did not provide a specific forecast, but said it expects sales and margins to improve in the second half of the upcoming fiscal year, as supply chain conditions ease.

Here’s how the retailer did in the three-month period ended Feb. 26 compared with what analysts were anticipating, based on Refinitiv data:

  • Loss per share: 92 cents vs. profit of 3 cents expected
  • Revenue: $2.05 billion vs. $2.07 billion expected

The company’s net loss grew to $159 million, or $1.79 per share, from net income of $9 million, or 8 cents a share, a year earlier. Excluding one-time items, it lost 92 cents a share. Analysts surveyed by Refinitiv had expected earnings per share of 3 cents.

Sales fell 22% to $2.05 billion from $2.62 billion a year earlier. That fell short of estimates for $2.07 billion.

Same-store sales, a key retail metric, dropped 12% across Bed Bath’s business compared with the year-ago period. Same-store sales declined 15% for the Bed Bath & Beyond banner and grew by low single-digits for the BuyBuy Baby banner.

Digital sales declined by 18% compared with the year-ago period, which partially reflects the shift back to stores and normalizing e-commerce levels.

Tritton said Bed Bath is doing a complete overhaul of its supply chain so it can better manage all of its merchandise as it imports goods and moves them to distribution centers and stores. He said that technology, which acts like “a virtual control tower,” will go live at the end of this month. Those efforts were already underway, but have become more urgent, he said.

“The timing of these pressures and the timing of the completion of the strategy is the friction point,” he said.

Along with executing on its turnaround efforts, Bed Bath must compete for shoppers’ dollars as inflation is at an approximately four-decade high. Consumers are also weighing other spending priorities, such as summer vacations and spring wardrobes, which may direct their attention outside of the home.

Tritton said the backdrop is tougher for the retailer, especially since households no longer have extra dollars from the government like child tax credits. That is “dampening the overall demand for several categories, including home,” he said.

“We think there’s an evergreen, strong home market that has had some erratic ups and downs and when it normalizes, we think there’s a great business to be had,” he said. “We’re part of customers’ lives and their wants and needs and to ensure that we’re in stock and servicing that need is our key agenda.”

As of Tuesday’s close, Bed Bath’s shares are up about 23% so far this year. The retailer’s stock closed at $17.97 on Tuesday, down 6.75%, bringing its market value to $1.73 billion.

Read the company’s earnings press release here.



Source

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push
Business

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push

U.S. Senator Elizabeth Warren (D-MA) and Director of the United States Office of Management and Budget, Russell Vought. Kevin Mohatt | Kevin Lamarque | | Reuters Sen. Elizabeth Warren on Friday accused the acting head of the Consumer Financial Protection Bureau of undermining President Donald Trump’s stated push to make credit cards more affordable, according […]

Read More
Why a niche category of CRE lending is suddenly seeing record deals
Business

Why a niche category of CRE lending is suddenly seeing record deals

Wepro | Moment | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight […]

Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Business

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase […]

Read More